Related Experiment Videos
Abnormalities in thrombin-antithrombin pathway in AL amyloidosis
1Department of Internal Medicine, University of Pavia, IRCCS Policlinico San Matteo, Italy.
Summary
Abnormal hemostasis in AL amyloidosis involves the thrombin-antithrombin pathway. Impaired antithrombin III activity and function contribute to a hypercoagulable state, despite frequent bleeding events.
Area of Science:
- Hematology
- Internal Medicine
- Pathophysiology
Background:
- AL amyloidosis is characterized by abnormal hemostasis.
- Imbalances in clotting factors and inhibitors may cause bleeding and thrombosis.
Purpose of the Study:
- To investigate the thrombin-antithrombin pathway in patients with AL amyloidosis.
- To understand the role of antithrombin III (ATIII) in hemostatic abnormalities.
Main Methods:
- Studied 35 AL amyloidosis patients, assessing thrombin time, antithrombin III activity (ATIII Act) and antigen (ATIII Ag), and thrombin-antithrombin (TAT) complexes.
- Utilized crossed immunoelectrophoresis of ATIII in the presence of heparin.
Main Results:
- Prolonged thrombin time observed in 29 patients.
- Significantly lower ATIII Act compared to ATIII Ag, with a loss of correlation.
- Elevated TAT complexes in 19 patients, with altered ATIII forms showing reduced heparin binding.
Conclusions:
- The thrombin-antithrombin pathway is impaired in AL amyloidosis.
- Reduced ATIII biological activity contributes to the hypercoagulable state.
- This impairment may explain thrombotic manifestations despite prevalent bleeding.